밍크 테라퓨틱스 (INKT) 주가 전망: 목표주가, 배당, 최신 뉴스

MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.

The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).

It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc.

to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.

MiNK Therapeutics, Inc.는 임상 단계의 바이오제약회사로, 암 및 기타 면역매개 질환 치료를 위해 동종(Allogeneic)·오프더셸프(off-the-shelf)·불변 자연살해 T(iNKT) 세포 치료제를 발굴·개발·제조·상용화합니다.

주력 파이프라인인 agenT-797는 오프더셸프 동종 네이티브 iNKT 세포치료제로, 이전 치료를 받은 진행성 식도·위·위식도 접합부 선암 환자를 대상으로 agenT-797와 botensilimab, balstilimab을 ramucirumab 및 paclitaxel과 병용하는 임상 2상에서 안전성·유효성을 평가 중입니다. 또한 항-PD-1 계열인 pembrolizumab, nivolumab과의 병용 단독요법으로 불응성 고형암 대상 임상 1상, 중등도~중증 바이러스성 급성호흡곤란증후군(ARDS) 치료를 위한 임상 1상도 진행하고 있습니다.

이외에도 MiNK-215(IL-15 armoring과 FAP-CAR-iNKT를 표적하는 종양 기질 타깃 프로그램)로 고형암 및 염증을, MiNK-413(IL-15 armoring CAR-iNKT로 B cell maturation antigen 표적)으로 이식편대숙주병 예방 등 자가면역질환 치료를 개발하고 있습니다. Autonomous Therapeutics, ImmunoScape, Inc., C-Further 등과 전이성 종양·고형암 표적 T세포수용체 치료제·PRAME 표적 소아암 iNKT 치료제 개발을 위한 협업을 진행 중입니다. 회사는 2017년 설립되었고, 2021년 6월 AgenTus Therapeutics, Inc.에서 MiNK Therapeutics, Inc.로 사명을 변경했으며 본사는 뉴욕에 있습니다.

• 주소: 149 Fifth Avenue, Suite 500, New York, NY 10010, United States

• 전화번호: 212 994 8250

• 웹사이트: https://minktherapeutics.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 15